This nonrandomized clinical trial assesses associations between psilocybin therapy and changes in systemic markers of inflammation and mitochondrial stress in people with Parkinson disease and mood dysfunction.
No takes yet. Share an insight, caveat, or question.
Bradley et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: